THE AMERICAN CANCER SOCIETY plans to double its annual funding for research by 2021. The society made the announcement in conjunction with Vice President Biden’s National Cancer Moonshot Summit at Howard University in Washington, D.C. ACS plans to increase its annual research investment to approximately $240 million by 2021. The organization currently spends about $100 […]
JOEL KATZ was honored by City of Hope with the Spirit of Life Award. Katz, an entertainment attorney, is chair of the Global Entertainment and Media Practice of Greenberg Traurig, and was recognized for his work in the entertainment industry. Katz will be presented with the award at a gala in Los Angeles Nov. 10. […]
FIRAS ELADOUMIKDACHI was named program director for the Rutgers Cancer Institute of New Jersey at Hamilton. He will be responsible for clinical leadership of the oncology service line at RWJ Hamilton including medical, surgical and radiation oncology. Eladoumikdachi is an assistant professor of surgery at Rutgers Robert Wood Johnson Medical School. He has been with […]
STEPHEN BURLEY was named as co-program leader of the Cancer Pharmacology Research Program at Rutgers Cancer Institute of New Jersey. Burley will work with co-program leader X.F. Steven Zheng, a university professor at Rutgers Robert Wood Johnson Medical School, in determining the mode of action and mechanism of resistance to anti-cancer agents and developing novel […]
Richard Pazdur, currently the director of the FDA Office of Hematology and Oncology Products, will serve as acting director of the newly formed FDA Oncology Center of Excellence.
Vice President Joe Biden announced the formation of the FDA Oncology Center of Excellence, which is intended to consolidate the agency's cancer portfolio and streamline regulatory pathways for cancer-related drugs, biologics, and devices.
After a year of trying to understand the biology and politics of cancer, Vice President Joe Biden admits that he has a stronger grasp on the nuts and bolts of Washington than the evolutionary mysteries known collectively as cancer.
Jonathan Hirsch was studying neuroscience at Stanford University when he wandered into two oncology classes and saw an opportunity to change the way health systems handle genomic data.
How will the success of the moonshot be measured? NCI Acting Director Doug Lowy touched on the subject during the joint meeting of the institute's Board of Scientific Advisors and the National Cancer Advisory Board June 21.
Three health systems—Stanford Cancer Institute, Intermountain Healthcare and Providence Health and Services—have agreed to eliminate the electronic barriers between their medical records, tumor registries and genomics databases.
